LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
The diabetes tech firm tailored its software to the 25 million people in the U.S. who have Type 2 diabetes and do not use insulin. The device is similar to existing prescription CGMs. Users pair the ...
Zacks.com on MSN
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter
DexCom DXCM received a warning letter from the FDA on March 4, 2025, following inspections of its San Diego and Mesa facilities in 2024. The FDA cited deficiencies in the company’s manufacturing ...
“The approval of Dexcom G7 15 Day marks another major innovation for Dexcom,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “By listening to the needs of our users, ...
DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ ...
Shares of DexCom (NASDAQ:DXCM) fell for the third straight session on Friday to reach the lowest level since April, even as ...
Dexcom’s continuous blood glucose monitoring systems help people living with diabetes track their blood sugar levels. The device connects to a person’s skin and provides continuous feedback to an app ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback